Skip to main
AORT
AORT logo

Artivion (AORT) Stock Forecast & Price Target

Artivion (AORT) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Artivion Inc. reported a notable operating margin of 17.8%, which reflects a year-over-year increase of 770 basis points and surpasses prior estimates, indicating strong operational efficiency. The company expects to continue its financial improvement with projected gross margin growth of approximately 100 basis points for 2025, along with an increase in research and development expenses and an EBITDA margin enhancement of 200 basis points. Furthermore, robust sales growth in key product lines, such as aortic stent grafts and On-X products, coupled with anticipated revenue contributions from new product launches, positions Artivion favorably for sustained revenue growth and margin expansion in the near future.

Bears say

Artivion Inc faces significant risks that contribute to a negative outlook on its stock, including potential delays in clinical trials and disappointing sales from new product launches, which may weaken operating margins. Recent financial performance highlights a concerning trend, with revenue growth declining to 3.5% in 4Q24 from 9.5% in the prior quarter, compounded by disruptions stemming from a cybersecurity incident that negatively impacted sales by approximately $4.5 million. Furthermore, while EBITDA margins showed improvement, the overall revenue guidance for 2025 fell slightly short of market expectations, raising doubts regarding the company's ability to sustain robust growth.

Artivion (AORT) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Artivion (AORT) Forecast

Analysts have given Artivion (AORT) a Buy based on their latest research and market trends.

According to 8 analysts, Artivion (AORT) has a Buy consensus rating as of Jul 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Artivion (AORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.